유전성 혈관성 부종 치료제 시장, 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Hereditary Angioedema Therapeutics Market was valued at USD 4.1 billion in 2023 and is projected to grow at a CAGR of 9.2% from 2024 to 2032. Key drivers include heightened awareness of hereditary angioedema (HAE) and advancements in diagnostic technologies, particularly enhanced genetic testing. These advancements lead to more diagnoses and an increasing patient population seeking effective treatments.

For example, the Rare Disease Advisor Report highlights that HAE episodes account for 15,000-30,000 emergency department visits annually in the U.S. A survey of U.S. physicians indicated that diagnosing HAE can take anywhere from 0-6 months to over a decade, with less than 38% of patients receiving an accurate diagnosis within 1-3 years of symptom onset. Growing awareness among healthcare professionals and patients, combined with breakthroughs in targeted therapies, is expected to propel market growth. These breakthroughs include new complement inhibitors and bradykinin B2 receptor antagonists.

Ongoing innovations in targeted therapies, especially new complement inhibitors and bradykinin B2 receptor antagonists, are fueling market expansion. These therapies, boasting superior efficacy and safety over traditional treatments, appeal to both patients and healthcare providers. For instance, in May 2024, Ionis Pharmaceuticals, Inc. reported promising outcomes from its Phase 3 OASIS-HAE and OASISplus studies. Their drug, donidalorsen, showcased a marked and sustained reduction in monthly HAE attack rates, with over 90% improvement even after a year, regardless of whether patients were dosed monthly or bi-monthly. Such advancements in drug development are broadening the therapeutic landscape for HAE, further bolstering market growth.

The overall HAE therapeutics market is divided based on treatment type, route of administration, age group, and region.

In 2023, the C1 esterase inhibitors segment led the market with revenues reaching USD 1.8 billion. As awareness and understanding of HAE have grown among both healthcare professionals and the public, earlier diagnoses and treatments have become more common. This surge in awareness has heightened the demand for C1 esterase inhibitors, the go-to treatment for acute HAE attacks. Recognized for their safety and effectiveness, C1 esterase inhibitors are increasingly preferred over broader treatment options. Furthermore, their rising use for long-term prevention in HAE patients underscores a significant market trend, especially with the industry's shift from reactive to preventive care.

The adult segment is projected to hit USD 5.1 billion by 2032. Thanks to advancements in diagnostics and heightened awareness, a growing number of adults are being accurately diagnosed with HAE. This surge in diagnoses has spurred demand for therapies tailored to adult needs. Adult patients, often more proactive in their treatment pursuits due to a deeper understanding of their condition, benefit from the efforts of patient advocacy groups and educational campaigns, further amplifying the demand for HAE therapies in this demographic.

North America, holding a significant 46.8% share in 2023, is poised to maintain its dominance in the global hereditary angioedema therapeutics market. The region's robust R&D infrastructure, particularly in the U.S., has facilitated the swift development and approval of novel HAE therapies. The concentration of top-tier pharmaceutical firms, esteemed academic institutions, and pioneering research organizations has catalyzed innovation, ushering advanced treatments into the market. Additionally, the proliferation of specialized clinics and treatment centers for rare diseases like HAE enhances patient access to care. These centers, equipped with the latest therapies, play a pivotal role in ensuring timely and effective treatment for patients, thereby bolstering market growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Advancement in targeted therapies for HAE
    • 3.2.1.2 Increasing incidence of HAE
    • 3.2.1.3 Advancement in diagnostic technologies
    • 3.2.1.4 Increasing shift towards personalized medicine
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory requirements for new HAE therapies
    • 3.2.2.2 High cost of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 C1-esterase inhibitor
• 5.3 Bradykinin B2 receptor antagonist
• 5.4 Kallikrein inhibitor
• 5.5 Other treatment types

Chapter 6 Market Estimates and Forecast, By Route of administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Parenteral

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pediatric
• 7.3 Adult
• 7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Drug store and retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Attune Pharmaceuticals
• 10.2 BioCryst Pharmaceuticals, Inc.
• 10.3 Biomarin
• 10.4 CSL Behring LLC
• 10.5 Intellia Therapeutics
• 10.6 Ionis Pharmaceuticals
• 10.7 KalVista Pharmaceuticals, Inc.
• 10.8 Pharming Healthcare, Inc.
• 10.9 Pharvaris
• 10.10 Takeda Pharmaceutical Company Ltd